Please assess the completion status of the following clinical trial:

Trial Title: Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with metastatic renal cell carcinoma, histopathologically confirmed~* Treated with sunitinib according to Smpc~* For cases: Achieving a CR (local assessment according to RECIST V1.0 criteria) with Sunitinib in prior 6 months alone OR in combination with local treatment (surgery, radiation therapy, ablative techniques: cryotherapy, RFA)~* For controls: Life expectancy \> 3 months No prior Sunitinib treatment~* Patient \>18 years~Exclusion Criteria:~* Sunitinib administered in a non-approved label~* For cases: CR occurring without sunitinib treatment~* For controls: Prior systemic treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Complete Remission (Type: None): Complete remission arm in mRCC patients treated with sunitinib.
- Non Complete Remission (Type: None): Non complete remission arm in mRCC patients treated with sunitinib.

Based on this trial design, predict the completion outcome and termination type (if applicable).